Compare
Neumora Therapeutics, Inc. vs Editas Medicine, Inc. vs Vaxart, Inc. vs Inhibikase Therapeutics, Inc.
| Latest fiscal year | Neumora Therapeutics, Inc. NMRA | Editas Medicine, Inc. EDIT | Vaxart, Inc. VXRT | Inhibikase Therapeutics, Inc. IKT |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $40.52M | $237.26M | n/a |
| Revenue growth (YoY) | n/a | +25.4% | +726.7% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -394.9% | 7.6% | n/a |
| Net margin | n/a | -395.0% | 6.9% | n/a |
| Net income | -$236.93M | -$160.06M | $16.33M | -$48.26M |
| EPS (Diluted) | -$1.45 | -$1.80 | $0.07 | -$0.49 |
| Operating cash flow | -$206.44M | -$165.24M | $7.71M | -$27.79M |
| Free cash flow | n/a | -$165.85M | $7.57M | -$27.80M |
| Cash & equivalents | $182.53M | $146.65M | n/a | $178.80M |
| Total assets | $191.05M | $186.53M | $186.08M | $181.20M |
| Total liabilities | $87.18M | $159.25M | $98.28M | $8.30M |
| Shareholders' equity | $103.87M | $27.29M | $87.80M | $172.90M |
| Return on year-end equity | -228.1% | -586.6% | 18.6% | -27.9% |
| Shares outstanding | 174.26M | 97.87M | 240.49M | 131.69M |
Revenue, most recent five fiscal years
| Fiscal year | Neumora Therapeutics, Inc. | Editas Medicine, Inc. | Vaxart, Inc. | Inhibikase Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $40.52M Ended 2025-12-31 | $237.26M Ended 2025-12-31 | $0 Ended 2024-12-31 |
| 1 year earlier | n/a | $32.31M Ended 2024-12-31 | $28.70M Ended 2024-12-31 | $260.5K Ended 2023-12-31 |
| 2 years earlier | n/a | $78.12M Ended 2023-12-31 | $7.38M Ended 2023-12-31 | $123.4K Ended 2022-12-31 |
| 3 years earlier | n/a | $19.71M Ended 2022-12-31 | $107.0K Ended 2022-12-31 | $3.10M Ended 2021-12-31 |
| 4 years earlier | n/a | $25.54M Ended 2021-12-31 | $892.0K Ended 2021-12-31 | $698.5K Ended 2020-12-31 |